{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-000576","form_type":"8-K","ticker":"SABS","cik":"0001833214","company_name":"SAB Biotherapeutics, Inc.","filed_at":"2023-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.935281+00:00","generated_at":"2026-06-20T17:14:40.256839+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"SAB Biotherapeutics completes GLP-tox study for SAB-142 T1D therapeutic; IND filing within 12 months","bullets":["SAB-142 well tolerated in GLP-tox study; dose-dependent pharmacologic effect confirmed.","First fully-human anti-thymocyte hpAB for type 1 diabetes; may avoid immune reactions seen with animal-derived antibodies.","SAB to submit IND filing within approximately 12 months.","SAB-142 dosed at 1, 5, and 10 mg/kg; prolonged lymphodepletion suggests potential for optimized dosing.","Potential to delay onset/progression of type 1 diabetes and other T-cell mediated autoimmune diseases."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-000576","json":"https://secwatch.observer/filing/0000950170-23-000576.json","markdown":"https://secwatch.observer/filing/0000950170-23-000576.md","text":"https://secwatch.observer/filing/0000950170-23-000576.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1833214/000095017023000576/0000950170-23-000576-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1833214/000095017023000576/sabs-20230110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T17:14:40.256839+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}